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Abstract
Background: Critical illness causes a shift away from mitochondrial metabolism
towards a greater dependence on glycolysis. This metabolic shift is thought to be
associated with lactic acidosis, organ dysfunction and poor clinical outcomes. The
current paradigm is that low oxygen supply causes regional hypoxia, which in turn
drives such a metabolic shift. In this study, we evaluated whether the shift towards
glycolysis can also occur in cells where oxygen supply is plentiful.
Methods: We used circulating blood cells from non-hypoxic critically ill patients (n = 47)
as a model to study cellular metabolism in a normal oxygen milieu. We measured the
transcriptomic profiles of canonical metabolic pathways in these cells and compared
them to cells obtained from healthy controls (n= 18).
Results: Transcriptomic profiling revealed a significant reprogramming of metabolic
pathways during critical illness. In well-oxygenated cells, there was a reduced expression
of tricarboxylic acid cycle genes and genes associated with pyruvate entry into the
mitochondria suggesting decreased mitochondrial oxidation. In contrast, glycolysis was
accelerated, as reflected by an up-regulation of genes coding for enzymes of early and
late glycolytic pathway that were associated with increased lactate production. The
pentose phosphate pathway genes for NADPH production were also up-regulated
suggesting enhanced antioxidant production during increased oxidative stress.
Conclusions: Contrary to the established paradigm, aerobic glycolysis does occur in
non-hypoxic cells during critical illness and its occurrence may represent an adaptive
strategy common to cells under increased oxidative stress. Further study of this
previously under-recognized metabolic phenomenon might identify novel drug target
for antioxidant therapy.
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Background
In health, energy production from carbohydrate substrates is predominantly driven by
mitochondrial oxidation and to a lesser extent by glycolysis. In times of increased
physiological stress, this mitochondrial/cytosol balance is reversed favouring glycolysis
as the dominant form of energy production [1]. Critical illness represents the most se-
vere form of physiological stress to the human host. Stressed leukocytes in septic pa-
tients, for example, shift from mitochondrial oxidation to an increased dependence on
glycolysis to meet their extraordinarily high metabolic demand (e.g. respiratory burst
or phagocytosis) [2]. The physiological trigger for this metabolic shift, however, is
largely unknown.
Intensive Care Medicine
Experimental
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Ischemia may cause the metabolic shift, based on the well-known observations
that anaerobic metabolism was associated with an increased glycolysis [3]. However,
this theory fails to account for many situations in which ischemia is not a promin-
ent feature (e.g. sepsis). An alternative explanation is that systemic inflammation
may trigger the glycolysis. This is based on studies showing that inflammation is
associated with a significant metabolic shift in activated leukocytes [2]. In addition,
emerging evidence showed that metabolic shift may actually represent an adaptive
physiological response to systemic inflammation in critical illness, even when an is-
chemic stimulus is absent [4]. This leads us to hypothesize that a metabolic switch
may occur in non-hypoxic conditions where ischemia is absent but systemic in-
flammation is a prominent feature, such as sepsis, trauma or surgery. To test our
hypothesis, we conducted a longitudinal study in patients with sepsis or systemic
inflammatory response syndrome (SIRS) to determine whether critical illness is
associated with a metabolic shift in cells with normal oxygen supply. We chose
sepsis and SIRS patients because systemic inflammatory response was a common
feature in these patients. We choose circulating leukocytes as our target tissue be-
cause these cells were bathed in oxygenated blood with plentiful supply of oxygen,
hence representing an ideal environment to study metabolic changes in a normal/
high oxygen milieu.
Method
Subjects
The study had a total of 65 subjects, including (1) 35 patients with sepsis, (2) 12
patients with SIRS and (3) 18 healthy volunteers as controls. The study protocol and its
raw data have been previously published elsewhere [5]. The study was approved by the
Sydney West Area Health Service Human Research Ethics Committee. Informed
written consent was obtained from all patients or their relative and from healthy
volunteers.
Systemic inflammatory response syndrome (SIRS) was defined as the presence of
at least two of the four clinical criteria: (a) fever or hypothermia (temperature
>38 °C [100.4 F] or <36 °C [96.8]); (b) tachycardia (>90 beats/min); (c) tachypnea
(>20 breaths/min or PaCO2 < 32 mmHg [4.3 kPa]) or the need for mechanical ven-
tilation; (d) an altered white blood cell count of more than 12,000 cells/L, less than
4000 cells/L, or the presence of more than 10 % band forms. Sepsis was defined as
bacterial infection in addition to the presence of at least two of the four criteria
above. The sepsis inclusion criteria required confirmation by microbiological cul-
ture and consensus by the consulting physician that sepsis was the cause of the pa-
tient’s presenting illness. The consulting physician was blind to the outcome
measures (see below) of the study.
Samples
We collected whole blood samples from each study participant within 24 h of admis-
sion to the intensive care unit, henceforth referred to as day 1. Daily samples collection
was performed for up to 5 days. Sample collection in healthy volunteers was performed
only on days 1 and 5.
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RNA extraction and microarray experiments
RNA extraction was performed using the standard protocol in batches of 12 to 24 samples
at a time (PAXgene Blood RNA kit; Qiagen, Germany). RNA quality was analysed using
the Agilent 2100 Bioanalyser (Agilent Technologies, Santa Clara, CA), and all samples
obtained an RNA integrity number of greater than 6.5, indicating high sample integrity.
Extracted RNA was stored at −80 °C until expression profiling using Illumina Sentrix
HT-12_v3_BeadChip arrays (Illumina, San Diego, California). Sample amplification and
labelling were carried out on 200 ng of total RNA using an Illumina TotalPrep Amplifica-
tion kit (Ambion, Austin, Texas) in batches of 24 samples at a time. Amplified cRNA was
assessed using the 2100 Bioanalyser to ensure satisfactory amplification. The samples were
then immediately hybridized onto HT-12_v3_BeadChips. Each sample (750 ng) was
loaded onto the arrays. The hybridization and washing procedure were identical for each
set of arrays processed and, after normalization, no significant batch effects were identi-
fied. To minimize experimental artefacts, all of the RNA extraction, sample amplification
and labelling, hybridization and washing and scanning procedures were carried out by the
same operator at the same time of the day.
Transcriptomic raw data were obtained by scanning of the microarray slides using
Illumina GenomeStudio V2010.3. Each probe on the array was passed through a filter
requiring a detection p value of <0.0050 in at least one sample to be included in any
further analyses. Of the 48,804 probes present on the Illumina HT 12 array, 24,840
probes (henceforth referred to as genes) passed this criterion. Genes that passed the
filtering were loaded into BRB ArrayTools, in which quantile normalization and log
transformation of the data were applied.
Gene-expression experiments
We used transcriptomic profiling to study the metabolic pathways since previous stud-
ies had shown that cellular metabolism was regulated at a transcriptional level [4, 6, 7].
Blood samples were collected into PAXgene tubes (Pre-Analytix, Switzerland) and were
subsequently processed for RNA extraction using the manufacturer’s protocol (PAX-
gene Blood RNA kit; Qiagen, Germany). Extracted RNA was then used in microarray
experiments using Illumina Sentrix HT-12_v3_BeadChip arrays (Illumina, San Diego,
California). Raw data were obtained by scanning of the microarray slides using Illumina
GenomeStudio V2010.3. Of the 48,804 probes present on the Illumina HT 12 array,
24,840 probes (henceforth referred to as genes) passed quality criterion. Additional in-
formation on the microarray experiments and the statistical methods used to analyse
the microarray data is provided in the Additional files 1, 2 and 3. Raw microarray data
of the entire data set is available in GEO (GSE54514).
Pathway analysis
We focused our analysis on genes involved in the canonical metabolic pathways of gly-
colysis, tricarboxylic acid cycle and pentose phosphate pathway. We performed a stu-
dent’s t test in each gene to compare the expression levels between the healthy controls
and critically ill patients. Differentially expressed genes that were identified to be statis-
tically significant were then visualized using PathVisio 3.2.1 and wikipathways
(WP534_78585_glycolysis; WP78_70014_TCA; WP134_68931_ppp; http://wikipathway-
s.org, accessed 05-05-201). The number of genes in each pathway is shown in Fig. 1.
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Statistical analysis
We focused our analysis on genes involved in the canonical metabolic pathways of
glycolysis, tricarboxylic acid cycle and pentose phosphate pathway. For each gene
involved in these pathways, we performed a t test to compare the expression level
between the healthy controls and the critically ill patients diagnosed with sepsis or
systemic inflammatory response syndrome. A threshold of p < 0.01 was used to determine
significance of differences observed.
Results
Patient characteristics
A total of 47 study subjects (35 sepsis and 12 SIRS) and 18 healthy volunteers were en-
rolled into our study. The study subjects had a wide range of critical illnesses, including
surgical and medical diseases involving several major organ systems (cardiovascular,
pulmonary, metabolic, renal, hepatic systems) (Table 1). All study subjects fulfilled cri-
teria for systemic inflammatory response syndrome. The mean arterial oxygen tension
levels were 124 mmHg (normal range 60–100 mmHg), indicating that the circulating
leukocytes were well oxygenated in most subjects. Furthermore, expression levels of
hypoxic-inducible factor 1-alpha (HIF1-α) gene in our patient were not increased argu-
ing against hypoxia (Additional file 2).
Fig. 1 a Metabolic pathways of circulating leukocytes from non-hypoxic critically ill patients. Data inside the
parentheses indicates the total number of genes (denominator) included in pathway analysis and the number of
genes (numerator) that were statistically significantly different between critically ill patients and healthy controls.
b Heat map of the glycolysis pathway. Each row represents a gene, and each column represents a sample. Red
colour denotes up-regulation, and blue colour denotes down-regulation. For critically ill patients, the study
period was 5 days. For healthy volunteers, the study period was 7 days. c Heat map of the tricarboxylic acid
pathway. Each row represents a gene, and each column represents a sample. Red colour denotes up-regulation
and blue colour denotes down-regulation. For critically ill patients, the study period was 5 days. For healthy
volunteers, the study period was 7 days
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Overall findings
We found major changes in the metabolic pathways of the critically ill patients com-
pared to the healthy controls. Nearly 50 % of the genes displayed changes during crit-
ical illness (Fig. 1a). Heat maps of the pathway genes revealed that these changes
followed a distinctive pattern (Fig. 1b, c). In the resting state (i.e. healthy controls), the
glycolytic pathway gene transcription was quiescent while that of tricarboxylic acid
cycle was active. During critical illness, this pattern was reversed; the glycolytic genes
became highly expressed while the previously active transcription of tricarboxylic acid
cycle genes was down-regulated (Fig. 1b, c). These findings suggested that a major re-
programming had occurred in the metabolic pathways of the cells.
Table 1 Patient demographics and clinical characteristics
Sepsis SIRS Healthy controls
Demographics
Number in group 35 12 18
Mean age (year) 64 61 43
Severity of illness
Mortality (%) 26 0 0
Mean APACHE II 20 16 NA
Vasopressor support (%) 72 16.8 0
Renal support (dialysis) (%) 26 8.3 0
Mechanical ventilation (%) 78 75 0
Presentation (n)a
Pulmonary infection 17 0 0
Urinary tract infection 4 0 0
Abdominal sepsis 6 0 0
Septicaemia 3 0 0
Soft tissue infection 3 0 0
Infective endocarditis 2 0 0
Post emergency surgery 7 1 0
Trauma 1 1 0
Myocardial infarction 0 3 0
Severe pancreatitis 0 1 0
Acute pulmonary oedema 0 2 0
Acute haemorrhage 0 2 0
Liver failure 0 1 0
Cardiogenic shock 0 2 0
Arrhythmias 0 2 0
Cerebral infarction 0 2 0
Pre-existing illness (n)a
Hypertension 9 7 3
Ischaemic heart disease 9 4 0
Chronic lung disease 8 2 0
Cancer 6 0 0
Diabetes 7 3 0
SIRS systemic inflammatory response syndrome, APACHE Acute Physiology and Chronic Health Evaluation
aSome patients have multiple conditions
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This metabolic reprogramming persisted throughout the study period (5 days).
Importantly, it did not vary with the severity of the illness since similar changes
were found in both SIRS and sepsis subgroups despite the fact that sepsis
subgroup had higher APACHE scores (hence more severe disease) and a lower
survival rate. Therefore, we present the data henceforth in reference to all patients
(“critically ill patients”) unless otherwise specified. Details of these changes are
given in Figs. 2, 3 and 4 (see below) and the full analysis are also provided in
Additional files 1, 2 and 3.
Fig. 2 Pathway diagram of the glycolysis pathway. Statistically significant genes (p < 0.01) (between critically ill
and healthy controls) are coloured in either red or green. Red colour denotes up-regulation, and green colour
denotes down-regulation. Lines with one-direction arrow (i.e. irreversible reaction) represent key regulatory
control steps of the pathway. Lines with arrows on both directions denote reversible reactions determined by
mass effect (i.e. forward and backward reaction can occur depending on substrate concentration)
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Major change (1)—glycolysis pathway
There are three main control points that regulate glycolysis. We found that genes for
two of the three control points were up-regulated in the critically ill patients compared to
the healthy controls (Table 2 and Fig. 2). The first was hexokinase (gene symbol: HK).
This enzyme converts glucose to glucose-6-phosphate, the essential first step of
glycolysis. We found gene-expression up-regulation in all three isoforms of this
enzyme (HK1, HK2, HK3), with one isoform (i.e. HK1) displaying the highest increase
in fold change (3.88–5.82) among all genes (Additional file 1: Table S1). The second
gene was pyruvate kinase (PKM2) and its expression level was also increased in the
critically ill patients compared to the healthy control. This enzyme controls the final
step of glycolysis; it produces energy (ATP) and pyruvate as end products. The
increased activity in these two main key control enzymes (i.e. hexokinase and pyruvate
kinase) would suggest that an accelerated glycolysis had occurred in the critically ill
patients. As further evidence, the glucose transporter gene SLC2A3 was up-regulated.
SLC2A3 has fivefold higher transport capacity than other isoforms of the same gene
(SLC2A1, SLC2A2 and SLC2A4). The up-regulation of this gene suggested that the
glucose transport across the cell membrane was at its maximal capacity, due to a high
glucose demand generated by an accelerated glycolysis.
We found additional evidence of increased glycolysis. In resting cells, G6PC provides
an exit point for excess glucose to leave the glycolytic pathway. Here, we found that
G6PC was significantly down-regulated, further corroborating that the condition was
favourable for an increased glycolysis (Fig. 2). In addition to an increased glycolysis, we
also observed gene-expression signals suggesting an increased downstream processing
Fig. 3 Pathway diagram of the genes in the pentose phosphate pathway. Statistically significant genes (p< 0.01)
(between critically ill and healthy controls) are coloured in either red or green. Red colour denotes up-regulation,
and green colour denotes down-regulation. Lines with one-direction arrow (i.e. irreversible reaction) represent key
regulatory control steps of the pathway. Lines with arrows on both directions denote reversible
reactions determined by mass effect (i.e. forward and backward reaction can occur depending on
substrate concentration)
Nalos et al. Intensive Care Medicine Experimental  (2016) 4:21 Page 7 of 15
of the glycolysis end product, the pyruvate (Fig. 2). This downstream processing
displayed two important features. First, the gene expression of LDHA was
up-regulated and that of LDHB down-regulated suggesting increased forward reaction of
lactate dehydrogenase (pyruvate→lactate) indicating that pyruvate was increasingly con-
verted to lactate. Second, this phenomenon was accompanied by the up-regulation of
SLC16A3 gene, which codes for monocarboxylate transporter 4 that shuttles lactate out of
the cell. In keeping with the above findings, we noted that gene-expression levels of the
two key glycolytic enzymes HK3 (first step in glycolysis) and LDHA (last step in glycolysis)
correlated with increased serum lactate (Additional file 1).
In summary, we observed transcriptional changes suggesting that the glycolytic path-
way has accelerated, as evidenced by (1) increased glucose transport into the cell, (2)
up-regulation of key enzymes and (3) increased end product. Interestingly, these
changes further suggest that pyruvate, the major end product, was converted into lac-
tate and subsequently shuttled out of the cell, thereby bypassing the tricarboxylic acid
cycle altogether. This was unexpected since traditional paradigm suggested that, when
the conditions were favourable (i.e. plentiful oxygen supply), pyruvate would enter the
tricarboxylic acid cycle for ATP synthesis; instead, we observed an increased transport
of pyruvate out of the cell.
Fig. 4 Pathway diagram of the genes in the tricarboxylic acid cycle. Statistically significant genes (p < 0.01)
(between critically ill and healthy controls) are coloured in either red or green. Red colour denotes up-regulation,
and green colour denotes down-regulation. Lines with one-direction arrow (i.e. irreversible reaction) represent key
regulatory control steps of the pathway. Lines with arrows on both directions denote reversible
reactions determined by mass effect (i.e. forward and backward reaction can occur depending on
substrate concentration)
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Major change (2)—pentose phosphate pathway
We found evidence that metabolic intermediates generated by increased glycolysis were
diverted to the pentose phosphate pathway (PPP). There were several findings to support
this. First, phosphofructokinase gene (PFK), a key regulatory enzyme in the early glycolytic
pathway, was down-regulated (including both isoforms PFKM and PFKL). This suggested
a substantial shift towards the PPP (Fig. 2). Further evidence of a diverted glycolysis was
provided by the genes PGM1 and PGM2. Enzymes encoded by PGM1 and PGM2 nor-
mally up-regulate in response to excessive glucose-6-phosphate present in the cytosol.
We found that their expression levels were increased, suggesting that acceleration towards
the PPP had indeed occurred. More direct evidence of an accelerated pentose phosphate
pathway was provided by up-regulation of genes coding for two key enzymes, glucose-6-
phosphate dehydrogenase (G6DP) and phosphogluconate dehydrogenase (PGD). They are
major enzymes in the early part of the pentose phosphate pathway (Table 3).
The pentose phosphate pathway consists of two parts: the early part (the oxidative
phase) is responsible for generating NADPH and the late part (the non-oxidative phase)
for biosynthesis (nucleic acids, enzymes or co-factor) [8]. We found a preferential up-
regulation of the early part over the late part (Table 3). Both NADPH-producing
enzymes (G6DP and PGD) displayed high gene-expression levels (Additional file 1),
indicating a substantially increased NADPH synthesis in these cells. There were two
further pieces of evidence to support preferential increase in NADPH production over
biosynthesis. First, the biosynthetic component of the pentose phosphate pathway was
down-regulated (Fig. 3). Second, in a post hoc analysis, we examined regulatory genes
that govern cell proliferation/growth (e.g. Myc, ATK1, PIK3, HIF1-α) [9]. This analysis
showed that there was no evidence of up-regulation in these genes (Additional file 2),
indicating that the cellular demand for biosynthesis was absent.
Major change (3)—tricarboxylic acid cycle
We observed a down-regulation in genes that control the entry point into the tricarb-
oxylic acid cycle (Fig. 4). This down-regulation occurred in all major genes of the
Table 2 Representative genes in glycolytic pathway
Symbols Isoforms Gene names Functions Roles in glycolysis Our
findings
SLC2A SLC2A1, SLC2A2,
SLC2A3, SLC2A4,
SLC2A5
Solute carrier family 2
facilitated glucose
transporter
Transport glucose
molecules across the cell
membrane
Provides glucose
for glycolytic
pathway
Up-
regulation
HK HK1, HK2, HK3 Hexokinase Initiate glycolysis by
conversion of glucose to
glucose-6-phosphate
The first essential
step in glycolysis
Up-
regulation
G6P G6PC Glucose-6-phosphate
catalytic subunit
Hydrolyse glucose-6-
phosphate to glucose
Reverse glycolysis Down-
regulation
PK PKM2, PKLR Pyruvate kinase Generates ATP and
pyruvate as the final
products
The final step in
glycolysis
Up-
regulation
LDH LDHA Lactate
dehydrogenase
Conversion of pyruvate to
lactate
Post-glycolysis
removal of
pyruvate
Up-
regulation
LDHB Lactate
dehydrogenase
Convert lactate back to
pyruvate
Provide pyruvate
for mitochondria
oxidation
Down-
regulation
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pyruvate dehydrogenase complex, namely, dihydrolipoamide S-acetyltransferase (DLAT),
component X (PDHX) and component beta (PDHB) (Table 4). There was additional evi-
dence of inhibition in the tricarboxylic acid cycle. First, the mitochondrial pyruvate carrier
gene (MPC1, MPC2) was not up-regulated, as would be expected in an environment of
an increased glycolysis (which would have resulted in more pyruvate transport into the
mitochondria). Second, malate dehydrogenase gene (MDH2) was also down-regulated. If
confirmed on a protein level, this down-regulation may represent less oxaloacetate avail-
able to combine with acetyl-CoA, the essential first step in the tricarboxylic acid cycle.
Third, isocitrate dehydrogenase genes (IDH3A, IDH3B) and malate dehydrogenase gene
(MDH2) were down-regulated (Table 4). The enzymes coded by those genes produce
NADH, the reducing potential carrier essential for oxidative phosphorylation in the mito-
chondria. In summary, we found transcriptomic evidence of inhibition in the tricarboxylic
acid cycle in terms of substrate supply, pathway initiation and relay into mitochondrial
oxidation. Together with an increased pentose phosphate pathway activity, these findings
suggest that the cell was shifting its activity away from mitochondria (oxidative) and mov-
ing towards the pentose phosphate pathway (reductive).
Discussion
Oxidative phosphorylation in the mitochondria is thought to be the most efficient path-
way for energy production in aerobic conditions [10]. This high efficiency comes with a
Table 3 Representative genes in pentose phosphate pathway
Symbols Gene names Functions Roles in pentose
phosphate pathway
Our
findings
G6PD Glucose-6-phosphate
dehydrogenase
Produce NADPH Rate-controlling
enzyme that initiates
the pathway
Up-
regulation
PGD Phosphogluconate
dehydrogenase
Produce NADPH Complete the oxidative
phase of the pathway
Up-
regulation
PRPS1 Phosphoribosyl
pyrophosphate
synthetase 1
Support biosynthesis of nucleotide Non-oxidative phase of
the pathway
Down-
regulation
RPE Ribulose-5-
phosphate-3-
epimerase
Support biosynthesis of nucleotide/
amino acid and support glucose
metabolism
Non-oxidative phase of
the pathway
Down-
regulation
Table 4 Representative genes in tricarboxylic acid cycle (TCA) pathway
Symbols Isoforms Gene names Functions Roles in TCA
pathway
Our
findings
IDH IDH3A,
IDH3B
Isocitrate dehydrogenase Decarboxylation of
isocitrate to 2-
oxoglutarate
Generate NADH
and carbon
dioxide
Down-
regulation
MDH2 MDH2 Malate dehydrogenase Oxidation of malate to
oxaloacetate
Generate NADH
and carbon
dioxide
Down-
regulation
PDHB PDHB Pyruvate dehydrogenase
component beta
Convert pyruvate to
acetyl-CoA
Entry point into
the TCA pathway
Down-
regulation
PDHX PDHX Pyruvate dehydrogenase complex,
component X
Convert pyruvate to
acetyl-CoA.
Entry point into
the TCA pathway
Down-
regulation
DLAT DLAT Pyruvate dehydrogenase complex
dihydrolipoamide S-
acetyltransferase
Convert pyruvate to
acetyl-CoA.
Entry point into
the TCA pathway
Down-
regulation
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cost; oxidative phosphorylation produces reactive oxygen species as a by-product. The
accumulation of reactive oxygen species (ROS) increases oxidative stress to the cell
with deleterious effects on function and cell survival [11]. In healthy cells, the harmful
effect of ROS is nullified by antioxidant NADPH (generated by pentose phosphate
pathway), such that a stable redox homeostasis is maintained. In critical illness, pro-
inflammatory cytokines (tumour necrosis factor-α, interleukin-1β) increase the amount
of ROS dramatically, thereby tilting the redox balance towards an oxidative environ-
ment [12]. Here, in a study of patients with systemic inflammatory response syndrome
and sepsis, we showed that circulating leukocytes might have adapted to this oxidative
environment by a reprogramming of metabolic pathways. This metabolic reprogram-
ming was suggested by gene-expression changes including (1) reduced substrate entry
into oxidative phosphorylation, (2) diverting substrate pyruvate away from oxidative
phosphorylation, (3) reduced activity of the tricarboxylic acid cycle, (4) increased sub-
strate supply to the pentose phosphate pathway, (5) increased NADPH production in
the pentose phosphate pathway and (6) reduced biosynthesis. The net outcome was an
increase in transcriptional activity of enzymes required for glycolysis, lactate production
and NADPH synthesis. A summary of these steps is given in Fig. 5.
Our data suggest that the driving force behind this reprogramming was an increased
dependence on aerobic glycolysis. The glycolytic pathway provided not only substrates
for energy production but also the enzymes that linked together key steps of this meta-
bolic reprogramming. The most notable example was pyruvate kinase (gene symbol:
PKM2), which participates in both glycolysis and redox homeostasis (Fig. 5). It is
known that two isoforms of pyruvate kinase exist in normal cells (PKM1, PKM2) [13].
In this study, we found that the gene for the slower isoform PKM2 was preferentially
Fig. 5 Summary of metabolic reprogramming and increased glycolysis in circulating leukocytes during
critical illness. (1) Reduced entry into the oxidative phosphorylation. (2) diverting pyruvate away from
oxidative phosphorylation. (3) Reduced activity in the tricarboxylic acid cycle. (4) Increased substrate supply
to the pentose phosphate pathway. (5) Increased NADPH production. (6) Reduced biosynthesis. PKM2
pyruvate kinase 2, NADPH nicotinamide adenine dinucleotide phosphate, NADH nicotinamide adenine
dinucleotide G-6-P glucose-6-phosphate
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expressed in the critically ill patients. This isoform PKM2 has a slower enzyme kinetic
such that its activation results in an accumulation of earlier glycolytic intermediates,
which may then be diverted towards the pentose phosphate pathway [14]. In addition,
PKM2 itself indirectly activates the pentose phosphate pathway, further facilitating the
NADPH production [15]. Finally, recent studies have demonstrated the presence of a
PKM2-ROS-pentose phosphate pathway feedback loop in human cells, further confirm-
ing the role of PKM2 up-regulation in redox balance [14]. Put together, these findings
suggest that glycolytic enzymes are part of an integrated network of redox homeostasis.
Our study is the first report to show that such a network may exist in critically ill
patients.
While novel within the critical care context, our finding that glycolysis participates in
metabolic reprogramming has been well observed in oncology [16]. Rapidly growing
cancer cells are known to mobilize the glycolytic pathway in order to recruit the pen-
tose phosphate pathway, which produces macromolecules (e.g. nucleic acid, protein,
lipid) to support cancer growth and proliferation. Our findings differ from these onco-
logical observations in one important aspect; that the recruitment of the pentose phos-
phate pathway was not for the purpose of biosynthesis but rather to increase NADPH
production. In critical illness, an ample supply of NADPH helps regulate cell function,
assists pathogen killing and protects against free radical damage.
Approximately 60 % of NADPH production in human is by the pentose phosphate
pathway [8]. The pentose phosphate pathway is normally quiescent (only 1.3 % of glu-
cose flux) but is up-regulated in cellular stress (30 % of glucose flux) [8]. Our study in-
dicated that this up-regulation occurred in patients with high oxidative load, such as
those with systemic inflammation (all our patients fulfilled diagnostic criteria for SIRS).
This finding is consistent with the current literature, which suggests critical illness gen-
erated a high oxidative burden in systemic circulation, especially in sepsis and SIRS pa-
tients [11, 17]. We also found that, in critically ill patients, this up-regulation was
accompanied by a reduction in the biosynthetic part of the pentose phosphate
pathway. This suggested that the cells had reprioritized its metabolic need towards
redox homeostasis (to repair injury), rather than nucleic acid synthesis (to support
growth). Additionally, we found evidence of inhibition in the electron transport
chain (the main producer of ROS under normal condition), indicating that the cell
may have entered into a self-protective mode by reducing pro-oxidants production.
Collectively, these findings represent cellular shifts towards increasing NADPH
while simultaneously decreasing oxidative load. Such shifts may help cells minimize
oxidative damage caused by inflammatory cytokines in blood.
Our study showed that an increased dependence on glycolysis could indeed occur in
aerobic conditions. The traditional paradigm predicts that, in aerobic conditions, mito-
chondrial oxidation is the preferred metabolic pathway [3]. Our finding showed an al-
ternative scenario. Such a finding suggested that the traditionally held assumption that
increased glycolysis (and hence hyperlactataemia) is an evidence of hypoxia or ischemia
may have limitations. It is likely that an increased aerobic glycolysis may represent an
adaptive physiological response to sepsis or systemic inflammation.
It is important to note that our findings are in keeping with recent advances on the
study of cellular metabolism. First, recent studies have found that metabolic repro-
gramming has occurred in human leukocytes. In the work performed by Liu et al.,
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human leukocytes (monocytes) underwent metabolic reprogramming in the early phase
of sepsis [18]. In the work performed by Tannahill et al., macrophages stimulated by
lipopolysaccharide underwent up-regulation of glycolysis [19]. Our study showed that
metabolic reprogramming has occurred in whole blood. Second, there is extensive evi-
dence that demonstrates the existence of each component of the metabolic reprogram-
ming, including aerobic glycolysis, pentose phosphate pathway up-regulation and
tricarboxylic acid cycle down-regulation [16]. We noted that all of these components
were evident in our findings. Third, there is evidence to show that cellular stress
(e.g. radiation injury, trauma) or adrenergic stimulation (e.g. shock) triggers metabolic
programming in the injured cells [20–23]. Our findings confirmed this observation and
further extended it by demonstrating its presence in an intensive care setting. Put to-
gether, our study adds substantial new evidence to support the notion that cellular metab-
olism may play an important role in regulating host response to critical illness.
This current study differs from previous ones in the following aspects. First, we iden-
tified significant global changes across multiple cellular pathways. In contrast, previous
studies focused on individual genes and their specific role in cellular metabolism. The
global approach adopted in this study revealed important new findings that would
otherwise been impossible to obtain in single gene studies. Second, our target tissue
was circulating leukocytes, the pivotal cells that mediate host immune response to crit-
ical illness. Important physiological changes occurring in these cells could impact on
disease outcomes and may provide new targets for novel drug therapy. Third, our find-
ings were observed in a wide variety of medical/surgical conditions and in patients with
different disease severity. This indicates that our findings were robust. Furthermore, it
suggests that metabolic reprogramming may be a well-conserved response in a range of
critical illnesses.
There are several limitations in our study. First, our findings were derived from tran-
scriptomic analysis; our study did not provide data from metabolic assays or directly
measure the degree of oxidative stress inside the cells. However, this had been previ-
ously demonstrated by Tannahill et al. [19]. Nevertheless, it would be useful to col-
laborate gene-expression data with metabolic/redox measurements, and indeed, we
plan to perform such a study in the future. Second, the increased expression levels
of certain genes may be confounded by variations in cell count within leukocyte
subsets (e.g. increased neutrophils in sepsis/SIRS). We addressed this issue in a
post hoc analysis; this analysis did not find any correlation between neutrophils
counts and glycolytic genes (Additional file 3). Such a finding is in keeping with a
previous study showing that an increase in glycolytic enzyme activity was inde-
pendent of neutrophil counts [22]. Nevertheless, we could not exclude the effect of
cell count on gene-expression (such effect, if present, was likely to be very small).
Third, our samples were whole blood, which consisted of heterogeneous popula-
tions of different leukocyte subsets (e.g., lymphocytes, neutrophils and monocytes).
We do not know whether metabolic reprogramming in different cell subsets oc-
curred to a different extent. We plan to address this study limitation in future
studies where cell subsets (instead of whole blood) will be used. Fourth, our cohort
included severely ill patients. It is not known whether patients with mild to moder-
ate illness also show similar findings. This is a further limitation of the study, and
it warrants further investigation in the future.
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Our findings have further research implications. Antioxidant therapy in critically ill
patients has attracted much attention in recent years [24]. However, current antioxidant
agents (e.g. selenium, glutamine) have not demonstrated success in improving patient
outcomes in recent clinical trials [25]. New antioxidant agents are therefore urgently
needed. Here, we provide a detailed roadmap of metabolic reprogramming in circulat-
ing leukocytes of critically ill patients. Further study of this road map and its main
regulator gene may identify highly valuable drug targets for antioxidant therapy in crit-
ical illness.
Conclusions
During critical illness, our study suggests that non-hypoxic cells up-regulate the glyco-
lytic pathway to re-direct substrates towards NADPH synthesis and to maintain redox
homeostasis. This previously under-recognized physiological phenomenon may reveal
important new drug targets for future development of antioxidant therapy.
Additional files
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Additional file 2: Analysis of regulatory genes that govern cell proliferation/growth.
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